AR and breast cancer: In this regard, clinical trials using enobosarm (selective AR modulator—SARM) or antiandrogens (i.e., bicalutamide and enzalutamide), when administered to ER+ BC patients, did not show clinical benefit rates (NCT02463032) [11,12].